Nasdaq: ANAC

Anacor Pharmaceuticals, Inc.

Anacor Pharmaceuticals is a biopharmaceutical company that engages in developing small-molecule therapeutics from its boron chemistry platform. It focuses on developing topical applications of its compounds to treat fungal, bacterial, and inflammatory diseases. The company’s primary product candidate, AN2690, is a novel topical antifungal for the treatment of toenail onychomycosis, a fungal infection of the nail and nail bed. It is also developing AN2728, an anti-inflammatory product candidate for the treatment of psoriasis; AN0128, a product candidate that has antibiotic and anti-inflammatory properties; and AN2718, which is in preclinical development for the topical treatment of vaginal candidiasis and tineapedis.